Sarah Sharman Moser
Overview
Explore the profile of Sarah Sharman Moser including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
92
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Apter L, Sharman Moser S, Arunachalam A, Gazit S, Hoshen M, Chodick G, et al.
Front Oncol
. 2024 Nov;
14:1442909.
PMID: 39512773
Background: Treatment for first-line (1L) metastatic non-small cell cancer (mNSCLC) changed with the introduction of immunotherapy. We describe treatment utilization and clinical outcomes in a real-world mNSCLC cohort in a...
2.
Sharman Moser S, Yaari S, Apter L, Poellinger B, Rheenen M, Arunachalam A, et al.
Cancer Epidemiol
. 2024 Oct;
93:102678.
PMID: 39357215
Introduction: We map the patient journey from symptom onset to intervention and describe primary treatment in a retrospective population-based cohort study of patients in a large healthcare-provider. Methods: Newly diagnosed...
3.
Apter L, Sharman Moser S, Gazit S, Chodick G, Hoshen M, Greenberg D, et al.
Oncologist
. 2024 Sep;
PMID: 39340826
Background: Treatment approach for metastatic non-small cell lung cancer (mNSCLC) has revolutionized in the recent decade with the introduction of immunotherapy and targeted medications in first-line (1L) therapy. We present...
4.
Sharman Moser S, Apter L, Livnat I, Ginsburg R, Yarden A, Drori M, et al.
Breast Cancer (Dove Med Press)
. 2024 Mar;
16:105-116.
PMID: 38464505
Background: In this observational study, we analyzed the treatment patterns and clinical outcomes of patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (mBC) who developed brain...
5.
Sharman Moser S, Apter L, Solomon J, Chodick G, Wollner M, Siegelmann-Danieli N
Anticancer Res
. 2023 Dec;
44(1):257-265.
PMID: 38159972
Background/aim: In this observational study, we analyzed the time on treatment (ToT) and overall survival (OS) of patients with metastatic non-small cell lung cancer (mNSCLC) in a 2.7-million-member public health...
6.
Leshem Y, Dolev Y, Siegelmann-Danieli N, Sharman Moser S, BPharm L, Chodick G, et al.
Cancer
. 2023 Nov;
130(2):324.
PMID: 37987227
No abstract available.
7.
Sharman Moser S, Mazursky O, Shalev H, Apter L, Chodick G, Siegelmann-Danieli N
Future Oncol
. 2023 Aug;
19(21):1473-1483.
PMID: 37529919
To describe treatment journey and clinical outcomes after palbociclib initiation in HR+/HER2- breast cancer patients across multiple lines. Adult patients (n = 559) were identified in a population-based study between...
8.
Leshem Y, Dolev Y, Siegelmann-Danieli N, Sharman Moser S, Apter L, Chodick G, et al.
Cancer
. 2023 Jun;
129(18):2789-2797.
PMID: 37354065
Background: Diabetes mellitus (DM) is a highly prevalent chronic metabolic disorder. Although DM has been associated with immune dysfunction, the effect of DM on the efficacy of immunotherapy is unknown....
9.
Sharman Moser S, Tanser F, Siegelmann-Danieli N, Apter L, Chodick G, Solomon J
J Pharm Policy Pract
. 2023 Feb;
16(1):22.
PMID: 36797806
In this article, we focus on the reimbursement process, and as an example, characterize the time to reimbursement of pembrolizumab, a PD-1 immune checkpoint inhibitor for treatment of metastatic NSCLC...
10.
Sharman Moser S, Chodick G, Gelerstein S, Barit Ben David N, Shalev V, Stein-Reisner O
BMC Psychiatry
. 2022 Aug;
22(1):541.
PMID: 35948895
Introduction: Major depressive disorder (MDD) is one of the most common mental disorders worldwide, estimated to affect 10-15% of the population per year. Treatment resistant depression (TRD) is estimated to...